Key facts
- This page summarizes Patrick Machado's Form 4 filing for Adverum Biotechnologies, Inc. (ADVM).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 14 Jun 2022, 16:19.
Patrick Machado - 10 Jun 2022 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)
- Reporting relationship
- Director
- Issuer ticker
- ADVM
- Reported as of
- 10 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Jun 2022, 16:19:31 UTC
- Prior SEC filing
- 01 Oct 2021
- Next SEC filing
- 16 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- Patrick Machado, by /s/ Ron A. Metzger, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Patrick Machado filed Form 4 for Adverum Biotechnologies, Inc. (ADVM) on 14 Jun 2022.
Change
- Previous filing in this sequence was filed on 01 Oct 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ADVM
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +40,000
- Change %
- Price
- $0.000000
- Shares after
- 40,000
- Date
- 10 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 40,000
- Exercise price
- $0.9903
- Footnotes
- F1
ADVM
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +12,500
- Change %
- Price
- $0.000000
- Shares after
- 12,500
- Date
- 10 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,500
- Exercise price
- $0.9903
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The shares subject to the option will vest on the earlier of June 10, 2023 or the 2023 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date.